Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05307835 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05307835 · ClinicalTrials.gov record · last posted 2025-12-02

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

StatusActive, Not Recruiting
PhasePhase 1
Started2021-12-02
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 2, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This research study is evaluating a new type of esophagus cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for esophagus cancer patients who have completed adjuvant therapy following neoadjuvant therapy and surgical resection. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of resectable esophagus cancer, so as to provide a new personalized therapeutic strategy.

Protocol amendment history 1 change detected by DataLookout

2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
WasSecond Affiliated Hospital, School of Medicine, Zhejiang University
NowSecond Affiliated Hospital, Zhejiang University, School of Medicine
Trial Details
NCT Number NCT05307835
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd.
Conditions Resectable Esophageal Cancer
Enrollment 27 participants
Start Date 2021-12-02
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-02